ASCOT LLA trial

From Aaushi
Jump to navigation Jump to search

Introduction

Industry funded, randomized, multicenter European trial designed to assess effects of statins in prevention of cardiovascular disease in hypertensive patients serum cholesterol < 251 mg/dL.

Lipid-lowering arm of ASCOT clinical trial.

Design:

Subjects:

Patients assigned to receive antihypertensive(s) plus atorvastatin 10 mg or placebo.

Primary endpoint: fatal & non fatal myocardial infarction.

Results:

More general terms

References

  1. Journal Watch 23(10):77, 2003 Sever PS et al, Lancet 361(Apr 5):1149, 2003 Lindhol LH & Samuelsson O, Lancet 361(Apr 5):1144, 2003